Monday, January 26, 2026 | 10:54 AM ISTहिंदी में पढें
Concord Biotech Ltd News
Antique maintains 'Buy' on Concord Biotech; sees strong API, CDMO growth
Antique expects the Concord to report revenue, Ebitda and PAT CAGR of 18 per cent, 17 per cent and 19 per cent, respectively, with margins remaining stable at around 42 per cent over FY25-28E
 "Antique maintains 'Buy' on Concord Biotech; sees strong API, CDMO growth")
Updated On : 06 Jan 2026 | 10:10 AM IST
Antique prefers domestic-focused pharma firms; resumes coverage on 4 stocks
Antique resumed coverage on Torrent Pharma with a 'buy' rating, Cipla and Dr Reddy's Lab with 'hold' ratings, and Concord Biotech with a 'buy' rating
 "Antique prefers domestic-focused pharma firms; resumes coverage on 4 stocks")
Updated On : 29 Dec 2025 | 11:24 AM IST
Looking for dividend? Keep an eye on these 13 stocks today; check full list
Here is the complete list of stocks that will remain in focus today as they are set to trade ex-dividend tomorrow, Wednesday, September 3, 2025
 "Looking for dividend? Keep an eye on these 13 stocks today; check full list")
Updated On : 02 Sep 2025 | 9:11 AM IST
Concord Biotech shares jump 6 per cent; here's what is fueling the gains
The upward movement in the pharmaceutical company's stock price followed an announcement regarding the company's Limbasi API facility
 "Concord Biotech shares jump 6 per cent; here's what is fueling the gains")
Updated On : 21 Aug 2025 | 3:05 PM IST